Ghent University Academic Bibliography

Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial

Raphael Koch, Lianne Haveman, Ruth Ladenstein, Benedicte Brichard, Heribert Jürgens, Sona Cyprova, Henk van den Berg, Wolf Hassenpflug, Anna Raciborska, Torben Ek, et al.

(2023) CLINICAL CANCER RESEARCH. 29(24). p.5057-5068

Add to list

Journal Article
A1
open access

Implementation of a centralized pharmacovigilance system in academic pan‐European clinical trials : experience from EU‐Response and conect4children consortia

Vida Terzić, Léa Levoyer, Mélanie Figarella, Elisabetta Bigagli, Noémie Mercier, Lucie De Gastines, Séverine Gibowski, Marius Trøseid, Jacques Demotes, Inge Christoffer Olsen, et al.

(2023) BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 89(4). p.1318-1328

Add to list

Journal Article
A1
open access

Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)

Angela Bellini, Ulrike Pötschger, Virginie Bernard, Eve Lapouble, Sylvain Baulande, Peter F. Ambros, Nathalie Auger, Klaus Beiske, Marie Bernkopf, David R. Betts, et al.

(2021) JOURNAL OF CLINICAL ONCOLOGY. 39(30). p.3377-3390

Add to list

Early impact of severe acute respiratory syndrome coronavirus 2 on pediatric clinical research : a Pan-European and Canadian snapshot in time

Olivier L. Mantha, Florence Flamein, Mark Turner (UGent) , Ricardo M. Fernandes, Régis Hankard, Ruth Ladenstein, Andrea Mikolasek, Daphné Christiaens (UGent) , Eva Degraeuwe (UGent) , Johan Vande Walle (UGent) , et al.

(2021) JOURNAL OF PEDIATRICS. 239. p.67-73.e3

Add to list

Journal Article
A1
open access

Topotecan-vincristine-doxorubicin in stage 4 high risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC : a SIOPEN study

Loredana Amoroso, Giovanni Erminio, Guy Makin, Andrew DJ Pearson, Penelope Brock, Dominique Valteau-Couanet, Victoria Castel, Marlène Pasquet, Genevieve Laureys (UGent) , Caroline Thomas, et al.

(2018) CANCER RESEARCH AND TREATMENT. 50(1). p.148-155

Add to list

Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis

Maria V Corrias, Stefano Parodi, Andrei Tchirkov, Tim Lammens (UGent) , Ales Vicha, Claudia Pasqualini, Catarina Träger, Yania Yáñez, Sandro Dallorso, Luigi Varesio, et al.

(2018) PEDIATRIC BLOOD & CANCER. 65(7).

Add to list

Risk stratification of high-risk metastatic neuroblastoma : a report from the HR-NBL-1/SIOPEN study

Daniel A Morgenstern, Ulrike Pötschger, Lucas Moreno, Vassilios Papadakis, Cormac Owens, Shifra Ash, Claudia Pasqualini, Roberto Luksch, Alberto Garaventa, Adela Canete, et al.

(2018) PEDIATRIC BLOOD & CANCER. 65(11).

Add to list

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations : the SIOPEN/HR-NBL1 and COG-A3973 trials

Ruth Ladenstein, Bieke Lambert (UGent) , Ulrike Potschger, Maria-Rita Castellani, Valerie Lewington, Zvi Bar-Sever, Aurore Oudoux, Anna Sliwinska, Katerina Taborska, Lorenzo Biassoni, et al.

(2018) EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. 45(2). p.292-305

Add to list

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN) : a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Poetschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Isaac Yaniv, Genevieve Laureys (UGent) , Penelope Brock, Jean Marie Michon, Cormac Owens, et al.

(2018) LANCET ONCOLOGY. 19(12). p.1617-1629

Add to list

Journal Article
A1
open access

Genomic amplifications and distal 6q loss : novel markers for poor survival in high-risk neuroblastoma patients

Pauline Depuydt, Valentina Boeva, Toby D Hocking, Robrecht Cannoodt (UGent) , Inge M Ambros, Peter F Ambros, Shahab Asgharzadeh, Edward F Attiyeh, Valérie Combaret, Raffaella Defferrari, et al.

(2018) JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 110(10).

Academic Bibliography

Zoledronic acid add-on therapy for standard-risk Ewing sarcoma patients in the Ewing 2008R1 trial

Implementation of a centralized pharmacovigilance system in academic pan‐European clinical trials : experience from EU‐Response and conect4children consortia

Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)

Early impact of severe acute respiratory syndrome coronavirus 2 on pediatric clinical research : a Pan-European and Canadian snapshot in time

Topotecan-vincristine-doxorubicin in stage 4 high risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC : a SIOPEN study

Event-free survival of infants and toddlers enrolled in the HR-NBL-1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis

Risk stratification of high-risk metastatic neuroblastoma : a report from the HR-NBL-1/SIOPEN study

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations : the SIOPEN/HR-NBL1 and COG-A3973 trials

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN) : a multicentre, randomised, phase 3 trial

Genomic amplifications and distal 6q loss : novel markers for poor survival in high-risk neuroblastoma patients

Contents

Support

Contact